New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2013
16:58 EDTZMHZimmer launches single injection pain relief solution at AAOS
Zimmer Holdings announced the introduction of Gel-One, Cross-linked Hyaluronate, at the 2013 American Academy of Orthopaedic Surgeons Annual Meeting, AAOS. Gel-One Hyaluronate is an injectable gel approved for the treatment of osteoarthritis of the knee.The product is a low volume viscosupplement designed to provide pain relief and improve knee joint function through a single-injection treatment.
News For ZMH From The Last 14 Days
Check below for free stories on ZMH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2014
10:02 EDTZMHOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:42 EDTZMHZimmer upgraded at Oppenheimer
Subscribe for More Information
06:29 EDTZMHZimmer upgraded to Outperform from Perform at Oppenheimer
July 24, 2014
15:11 EDTZMHZimmer valuation not reflecting Biomet deal potential, says Cantor
Cantor says Zimmer remains its preferred name in orthopedics despite its "disappointing" Q2 report, as the firm believes the stock's valuation doesn't properly reflects the potential from its tie-up with Biomet. Cantor thinks Zimmer management's synergy targets are possibly conservative and raised its price target on the stock to $117 from $113.
08:27 EDTZMHZimmer 'confident' Biomet merger transaction to be completed in 1Q15
Subscribe for More Information
08:25 EDTZMHZimmer sees FY14 gross margin ratio at 73%-74%
Expects FY14 SG&A to be unchanged, although it says there will be a seasonally higher ratio in Q3. Sees FY14 tax rate of 25.5%.
08:25 EDTZMHZimmer sees Q3 EPS $1.29-$1.31, consensus $1.37
Subscribe for More Information
08:19 EDTZMHLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
07:48 EDTZMHZimmer cuts FY14 EPS to $6.00-$6.10 from $6.00-$6.20, consensus $6.12
Subscribe for More Information
07:47 EDTZMHZimmer reports Q2 adjusted EPS $1.49, consensus $1.49
Reports Q2 revenue $1.18b, consensus $1.21B
July 22, 2014
08:15 EDTZMHZimmer should be bought on any weakness from Q2 results, says RBC Capital
RBC Capital believes that consensus Q2 recon estimates for Zimmer may be "a bit optimistic," but the firm thinks that investors already partially anticipate a miss on that metric The firm recommends buying the stock on any weakness associated with Q2 results, as it thinks the company's valuation is favorable, given its growth outlook. RBC Capital keeps a $120 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use